results (16, 17) . Some authors found normal Lp(a) levels in hypertensive patients (18) , whereas the others documented elevated Lp(a) levels (19) . Sechi et al. (20) found that Lp(a) levels were the best predictor of target-organ damage. This relation was independent of the level of blood pressure. Gazzaruso et al. (21) found that Lp(a) levels and apo(a) phenotypes in CHDfree patients with newly diagnosed essential hypertension were similar to those in controls, but the family history of CHD was strongly associated with high Lp(a) levels and apo(a) isoforms.
In order to study the possible role of Lp(a) in the development of CHD in hypertensive patients, we evaluated Lp(a) levels in a group of essential hypertensive patients and compared the hypertensives who had CHD with those who had not CHD.
Material and Methods

Patients and Study Design
Lp(a) levels were evaluated in patients with essential hypertension. The hypertensives were divided in two subgroups according to whether they had CHD or not (45 patients with essential hypertension without CHD and 45 hypertensive patients with CHD). To compare Lp(a) plasma levels we recruited a group of 64 healthy controls matched for age and sex. The criterion for inclusion in the patients group was essential hypertension defined either by the need for chronic antihypertensive treatment, or, in untreated subjects, by a diastolic blood pressure (DBP) greater than 80 mmHg or a systolic blood pressure (SBP) greater than 130 mmHg, or both on three different occasions at least 1 week apart. Blood pressure was measured by a mercury sphygmomanometer in standard conditions, and diagnosis of hypertension was established by standard criteria. A mean duration of hypertension was 10 ± 2.4 years. CHD was defined as documented previous myocardial infarction (diagnosed by elevation of cardiac enzyme levels and diagnostic change in their electrocardiogram); coronary artery disease documented by angiography (stenosis of > 70% in at least one coronary artery); coronary artery bypass grafting; or a history of angina pectoris together with a positive exercise test. In the other patients their medical history and an exercise stress test excluded the possibility of CHD. Exclusion criteria were: patients age >50 years, severe obesity, diabetes mellitus, pregnancy, stroke, renal failure with creatinine clearance of <30 mL/min, urinary protein excretion >3.0 g/d and use of cyclic hormonal therapy, lipid-lowering therapy and anticoagulant therapy. Approval from the appropriate local Ethics Committee was obtained and subjects gave their written informed consent.
Laboratory measurements
The following lipids were measured: total choles-
]. Blood was taken from the antecubital vein in seated patients who had fasted for 12 h. For the quantification of Lp(a) we used plasma obtained by addition of EDTA and low-speed centrifugation at 4 °C for 15 min. Serum cholesterol and triglyceride levels were determined by automated enzymatic methods using the Abbott autoanalyzer. Levels of HDL cholesterol were enzymatically determined in the supernatant after precipitation of other lipoproteins with phosphotungstate/magnesium chloride. Lowdensity lipoprotein (LDL) cholesterol was calculated by Friedewald's formula (22) . Measurement of Lp(a) was determined in freshly isolated sera using a rate nephelometric assay (Behring-Laser nephelometer Modul I). For the nephelometric measurement of Lp(a), polystyrene microbodies coated with antibodies to human Lp(a) were agglutinated when mixed with serum containing Lp(a). Elevated Lp(a) were defined as ≥ 0.30 g/L.
Statistical analysis
Statistical analysis was perfomed using the STA-TISTICA 4.5 program (Stat soft, Tulsa, OK USA). All values are expressed as mean ± SD. The Student's ttest was used for comparison between two groups and analysis of variance for comparison of more than two groups. Pearson's c 2 test was uased to compare frequency distributions. The Kruskal-Wallis test was used to compare variables with skewed frequency distribution. Results were considered statistically significant at p < 0.05.
Results
The features of hypertensive patients with coronary heart disease (CHD), hypertensive and controls, are shown in Table I . The two groups of hypertensive patients had no significant differences in age, sex, body mass index (BMI), duration of hypertension, SBP and DBP. Regarding lipid profile, several differences were observed between hypertensive and control subjects (Table II) . Serum levels of Lp(a) were significantly greater in hypertensive patients with CHD (0.33 ± 0.17 g/L) than in controls (0.18 0.08 g/L p<0.001) or hypertensive patients without CHD (0.20 ± 0.05 g/L p<0.001). Serum levels of Lp(a) were increased more than 0.30 g/L in 46.6% of CHD hypertensive patiens, 17.7% of hypertensive patiens and 8.8% of controls. The Lp(a) levels increased more than 0.50 g/L we found in 15.5% of CHD hypertensive patiens and 6.6% of hypertensive patients. No differences in serum Lp(a) levels, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were observed between hypertensive patients without CHD and controls. Hypertensive CHD patients had also greater levels of total cholesterol, LDLcholesterol and triglycerides than hypertensive patients and controls. Plasma HDL cholesterol were significantly lower in hypertensive CHD patients.
Discussion
In this study the presence of arterial hypertension is associated with increased Lp(a) levels. We hypothesize that hypertensive patients with high Lp(a) levels might have an earlier development and a more rapid progression of atherosclerotic lesions. We showed a possible relationship between Lp(a) and development of CHD among hypertensive patients with CHD younger than 50 years. The main finding of this study is that Lp(a) could play a considerable role in the development of CHD in hypertensive patients especially in those with concomitant abnormal lipid profiles. We recently found that Lp(a) plasma levels in CHD-free patients with essential hypertension were similar to those in controls. We showed that Lp(a) are not strongly linked to essential hypertension in a group of hypertensive patients without CHD. It is very important to know whether or not Lp(a) levels play a role in the development of CHD in hypertensives, who already have a high cardiovascular risk. Nevertheless, in essential hypertensive patients the cardiovascular risk related to Lp(a) (genetically inherited) is added to the CHD risk caused by hypertension and other risk factors associated with hypertension. Because hypertension and abnormal lipid metabolism are consistently found in hypertensive patients, such an interaction might accelerate atherosclerosis and its important consequences.
There is a strong link between high blood pressure and coronary heart disease (CHD) (23) . This close association does not mean that hypertension is the only cause of CHD in hypertensives, since several other cardiovascular risk factors are more prevalent among hypertensive patients than they are among normotensive subjects (24) .
Lp(a) exscess may promote premature atherosclerosis by the following mechanisms: inhibition of clot lysis by Lp(a) leading to a thrombogenic state (25 ' 28) , increased binding to proteoglycans (29) or to the very low density lipoprotein (VLDL) receptor (30) . Lp(a) also promotes increased uptake by macrophages, direct chemoattraction of monocytes (31) with induction of monocyte chemotactic activity in endothelial cells (32) and promotion of smooth muscle cell proliferation by blocking the plasmin-dependent activation of transforming growth factor-b (TGF-b) (33) . Oxidized Lp(a) may also contribute directly to accumulation of lipids in macrophages (34) .
While these several mechanisms appear to suggest that Lp(a) can act independently to promote atherosclerosis, further considerations suggest dependJugoslov Med Biohem 2003; 22 (4) 343
Hypertensive CHD patients (n=45) 7.50 ± 1.07*** 5.25 ± 0.64*** Therefore and because Lp(a) increases the risk of coronary events strongly depending on the presence of additional coronary risk factors, it is imperative to strictly control additional risk factors in individuals with elevated Lp(a) (39, 40) .
This study indicates that high Lp(a) levels can play a major role in the development of CHD in patients with essential hypertension. These findings suggest the great importance of identifying, among hypertensive patients, subjects with higher levels of Lp(a), which is added to the cardiovascular risk related to their hypertension. Further studies are required to elicit cause and effect in the relationship between arterial hypertension and Lp(a) and other lipoprotein disorders in hypertensive patients. In addition, our findings might have implications not only on the prognosis but also on the management of hypertensive patients. 
